Biologics Concerns Shift From IP To Bioterrorism

Law360, New York (March 19, 2009, 12:00 AM EDT) -- Biologic drugs have recently become an intellectual property issue for lawmakers, and now they are being targeted for bioterrorism concerns, with a Republican senator unveiling a bill that aims to prevent the U.S. Food and Drug Administration from using federal funds to consider biologics license applications for products by companies that do business with terrorists.

The legislation, known as S. 613 – unveiled in the U.S. Senate on Tuesday by Sen. Samuel Brownback, R-Kan. – would prohibit the FDA from using federal funds to process biologics...
To view the full article, register now.